New drug MTX-101 enters first human tests for type 1 diabetes

NCT ID NCT06324604

Recruiting now Disease control Sponsor: Mozart Therapeutics Australia Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called MTX-101 in healthy adults and people with type 1 diabetes. The main goal is to check for side effects, see how long the drug stays in the body, and learn how it affects immune cells. About 96 participants will receive either a single dose or multiple doses of the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS TYPE 1 DIABETES

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Austin Health
RECRUITING

Heidelberg, Victoria, 3084, Australia

Contact
St Vincent's Hospital Melbourne (SVHM)
RECRUITING

Fitzroy, 3065, Australia

Contact
The Royal Melbourne Hospital
RECRUITING

Melbourne, Victoria, 3050, Australia

Contact